1
|
Crawford K, Low JK, Le Page AK, Mulley W, Masterson R, Kausman J, Cook N, Mount P, Manias E. Transition from a renal paediatric clinic to an adult clinic: Perspectives of adolescents and young adults, parents and health professionals. J Child Health Care 2022; 26:531-547. [PMID: 34180271 DOI: 10.1177/13674935211028410] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The management of chronic kidney disease is complex. With disease management being the responsibility of parents in the paediatric renal clinic, the responsibility is gradually shifted to adolescents and young adults during the transition to adult care. This multi-perspective qualitative study aimed to explore the experiences of adolescents and young adults, their parents and health professionals to gain an insight into transitional care. Focussing on the transition process and transfer to adult care, 18 adolescents and young adults and eight mothers participated in individual semi-structured interviews. Additionally, three focus groups were conducted with 20 multidisciplinary health professionals. Data were transcribed verbatim and analysed thematically. Similar responses from adolescents and young adults and mothers included the reluctance to leave the paediatric health service. Mothers found the transition to adult care more challenging than the adolescents and young adults. While health professionals acknowledged that engaging adolescents and young adults in their own care was challenging, they believed parents had an important role in facilitating their child's independence. This study highlights that health professionals in both paediatric and adult health services need to work collaboratively. However, importantly, health professionals need to be mindful that parents require an equal amount of engagement as adolescents and young adults, if not more, to mitigate parental barriers in achieving a successful transfer.
Collapse
Affiliation(s)
- Kimberley Crawford
- Monash Nursing and Midwifery, 2541Monash University, Clayton, VIC, Australia
| | - Jac Kee Low
- School of Nursing and Midwifery, Centre for Quality and Patient Safety Research, Institute for Health Transformation, 2104Deakin University, Melbourne, VIC, Australia
| | - Amelia K Le Page
- Department of Nephrology, 557360Monash Children's Hospital, Clayton, VIC, Australia
| | - William Mulley
- Department of Nephrology, Monash Medical Centre, Clayton, VIC, Australia.,Department of Medicine, Centre for Inflammatory Diseases, 2541Monash University, Clayton, VIC, Australia
| | - Rosemary Masterson
- Department of Nephrology, 6453The Royal Melbourne Hospital, Melbourne, VIC, Australia.,Department of Medicine, 2281The University of Melbourne, Parkville, VIC, Australia
| | - Joshua Kausman
- Department of Nephrology, 6453Royal Children's Hospital, Melbourne, VIC, Australia.,Murdoch Children's Research Institute, 6453Royal Children's Hospital, Melbourne, VIC, Australia
| | - Natasha Cook
- Department of Nephrology, 3805Austin Health, Heidelberg, VIC, Australia
| | - Peter Mount
- Department of Nephrology, 3805Austin Health, Heidelberg, VIC, Australia.,Department of Medicine, Austin Health Faculty of Medicine, Dentistry and Health Sciences, 2281The University of Melbourne, Parkville, VIC, Australia
| | - Elizabeth Manias
- School of Nursing and Midwifery, Centre for Quality and Patient Safety Research, Institute for Health Transformation, 2104Deakin University, Melbourne, VIC, Australia.,Department of Medicine, The Royal Melbourne Hospital, 2281The University of Melbourne, Parkville, VIC, Australia
| |
Collapse
|
2
|
Martin K, Cantwell L, Barraclough KA, Lian M, Masterson R, Hughes PD, Chow KV. Prolonged immunosuppression does not improve risk of sensitisation or likelihood of re-transplantation after kidney transplant graft failure. Transpl Int 2021; 34:2353-2362. [PMID: 34320262 DOI: 10.1111/tri.13998] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Revised: 07/20/2021] [Accepted: 07/23/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND The optimum approach toward immunosuppression withdrawal following kidney transplant failure is unclear. Prolonged weaning may be associated with reduced sensitisation, less graft nephrectomy and greater likelihood of re-transplantation, but conversely increased risk of infection, malignancy and death. METHODS We conducted a single centre retrospective analysis of patients experiencing graft failure between 2007-2017, comparing rates of sensitisation, re-transplantation, nephrectomy, infection, malignancy and death between patients who had immunosuppression weaned over <90 vs. 90-180 vs. >180 days. RESULTS Patient survival after immunosuppression withdrawal over <90 vs. 90-180 vs. >180 days was 73.3%, 72.1% and 80.4% respectively (p=0.35), with no differences in cPRA (80.06 vs. 81.21 vs. 85.42, p=0.66) or re-transplantation rate (24/31 (77.4%) vs. 21/35 (60.0%) vs. 22/36 (61.1%), p=0.13). There was significantly less nephrectomy after late immunosuppression cessation (10/42 (23.8%) vs. 7/42 (16.7%) vs. 3/43 (7.0%), p=0.01) but no differences in infections or malignancy. On competing risk regression (death as competing risk) controlling for cofactors including age, nephrectomy and rejection, prolonged immunosuppression did not predict likelihood of re-transplantation (SHR 1.000, p=0.88). CONCLUSIONS Prolonged immunosuppression withdrawal does not reduce sensitisation or improve re-transplantation rates but is associated with less nephrectomy. Immunosuppression withdrawal should be tailored to individual circumstances after graft failure.
Collapse
Affiliation(s)
- Kylie Martin
- Department of Nephrology, Royal Melbourne Hospital, Victoria, Australia
| | - Linda Cantwell
- Victorian Transplantation and Immunogenetics Service, Australian Red Cross Life Blood, Victoria, Australia
| | - Katherine A Barraclough
- Department of Nephrology, Royal Melbourne Hospital, Victoria, Australia.,Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia
| | - Michael Lian
- Department of Nephrology, Royal Melbourne Hospital, Victoria, Australia
| | - Rosemary Masterson
- Department of Nephrology, Royal Melbourne Hospital, Victoria, Australia.,Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia
| | - Peter D Hughes
- Department of Nephrology, Royal Melbourne Hospital, Victoria, Australia.,Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia
| | - Kevin V Chow
- Department of Nephrology, Royal Melbourne Hospital, Victoria, Australia.,Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia
| |
Collapse
|
3
|
Ruderman I, Rajapakse CS, Opperman A, Robertson PL, Masterson R, Tiong MK, Toussaint ND. Bone microarchitecture in patients undergoing parathyroidectomy for management of secondary hyperparathyroidism. Bone Rep 2020; 13:100297. [PMID: 32760761 PMCID: PMC7393533 DOI: 10.1016/j.bonr.2020.100297] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 07/03/2020] [Accepted: 07/06/2020] [Indexed: 12/14/2022] Open
Abstract
Background Secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) leads to complex bone disease, affecting both trabecular and cortical bone, and increased fracture risk. Optimal assessment of bone in patients with CKD is yet to be determined. High-resolution magnetic resonance imaging (MRI) can provide three-dimensional assessment of bone microarchitecture, as well as determination of mechanical strength with finite element analysis (FEA). Methods We conducted a single-centre, cross-sectional study to determine bone microarchitecture with MRI in CKD patients with SHPT undergoing parathyroidectomy. Within two weeks of surgery, MRI was performed at the distal tibia and biochemical markers of SHPT (parathyroid hormone [PTH] and alkaline phosphatase [ALP]) were collected. Trabecular and cortical topological parameters as well as bone mechanical competence using FEA were assessed. Correlation of MRI findings of bone was made with biochemical markers. Results Twenty patients with CKD (15 male, 5 female) underwent MRI at the time of parathyroidectomy (16 on dialysis, 3 with functioning kidney transplant, one pre-dialysis with CKD stage 5). Median PTH at the time of surgery was 138.5 pmol/L [39.6–186.7 pmol/L]. MRI parameters in patients were consistent with trabecular deterioration, with erosion index (EI) 1.01 ± 0.3, and trabecular bone volume (BV/TV) 10.8 ± 2.9%, as well as poor trabecular network integrity with surface-to-curve ratio (S/C) 5.4 ± 2.3. There was also evidence of reduced cortical thickness, with CTh 2.698 ± 0.630 mm, and FEA demonstrated overall poor bone mechanical strength with mean elastic modulus of 2.07 ± 0.44. Conclusion Patients with severe SHPT requiring parathyroidectomy have evidence of significant changes in bone microarchitecture with trabecular deterioration, low trabecular and cortical bone volume, and reduced mechanical competence of bone.
Collapse
Affiliation(s)
- Irene Ruderman
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), The University of Melbourne, Parkville, Victoria, Australia
| | - Chamith S Rajapakse
- Departments of Radiology and Orthopaedic Surgery, University of Pennsylvania, PA, USA
| | - Angelica Opperman
- Departments of Radiology and Orthopaedic Surgery, University of Pennsylvania, PA, USA
| | - Patricia L Robertson
- Department of Radiology, The Royal Melbourne Hospital and The University of Melbourne, Parkville, Victoria, Australia
| | - Rosemary Masterson
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), The University of Melbourne, Parkville, Victoria, Australia
| | - Mark K Tiong
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), The University of Melbourne, Parkville, Victoria, Australia
| | - Nigel D Toussaint
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), The University of Melbourne, Parkville, Victoria, Australia
| |
Collapse
|
4
|
Holt SG, Kotagiri P, Hogan C, Hughes P, Masterson R. The potential role of antibodies against minor blood group antigens in renal transplantation. Transpl Int 2020; 33:841-848. [PMID: 32619297 DOI: 10.1111/tri.13685] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 05/18/2020] [Accepted: 06/25/2020] [Indexed: 12/29/2022]
Abstract
Blood group antigens are red blood cell (RBC) surface markers comprising specific carbohydrate moieties attached to the glycolipids and glycoproteins within the membrane. In addition to the major ABO blood group antigens, at least 35 minor blood group antigens have been defined to date. These antigens have immunogenic potential and may cause a transfusion reaction. There is evidence for renal expression of antigens from the Kidd, MNS, Duffy and Lewis groups and therefore the potential for antibodies directed against these antigens to cross-react in a transplanted kidney. In individuals lacking a specific RBC antigen, antibodies may develop after de novo exposure to that antigen, in addition to the potential presence of pre-existing innate antibodies. Relatively little attention has been paid to non-ABO system antibodies, with most reports in the literature focusing on transfusion reactions rather than on any putative role in allograft rejection. Here, we review each of these antigens in the context of renal transplantation and what limited evidence there is on how such immunological risk may be assessed and managed.
Collapse
Affiliation(s)
- Stephen G Holt
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Department of Medicine (RMH), The University of Melbourne, Melbourne, VIC, Australia
| | - Prasanti Kotagiri
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, VIC, Australia
| | - Chris Hogan
- Department of Haematology, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Australian Redcross, Melbourne, VIC, Australia
| | - Peter Hughes
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Department of Medicine (RMH), The University of Melbourne, Melbourne, VIC, Australia
| | - Rosemary Masterson
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, VIC, Australia.,Department of Medicine (RMH), The University of Melbourne, Melbourne, VIC, Australia
| |
Collapse
|
5
|
Ying T, Wong G, Lim W, Kanellis J, Pilmore H, Campbell S, Masterson R, Walker R, O'Connell P, Russ G, Chadban S. De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study. Am J Transplant 2018; 18:2977-2986. [PMID: 29802791 DOI: 10.1111/ajt.14948] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Revised: 05/08/2018] [Accepted: 05/20/2018] [Indexed: 01/25/2023]
Abstract
Choice of immunosuppression may modify the risk of cancer after kidney transplantation, however, long-term data are lacking. Using the Australian and New Zealand Dialysis and Transplant Registry, we compared the 9-year risk of incident cancer, non-melanoma skin cancer (NMSC), and death attributed to cancer among participants from Australia and New Zealand in four randomized-controlled trials which compared de novo or early switch to an everolimus-containing regimen with calcineurin-inhibitor-based triple therapy. An adjusted Cox-model with random effects was used to determine such risks. Two hundred seventy-nine patients (192 everolimus, 87 control) were followed for a median of 9 years (IQR 6.7, 11.2). Compared with control, everolimus use was not associated with a reduction in the risk of incident cancer, NMSC, or cancer-related death (unadjusted HR [95% CI] 0.86 [0.49-1.48], 0.58 [0.30-1.12], and 1.18 [0.32-4.38], respectively). Subgroup analyses showed a 56% reduction for NMSC in patients randomized to everolimus + reduced-dose calcineurin-inhibitor versus control (unadjusted HR 0.44 [0.21-0.92]), which remained significant after adjusting for age, gender and smoking (adjusted HR 0.45 [0.21-0.96]). Although de novo or early switch to everolimus did not alter the 9-year risk of incident cancer or cancer-related death, everolimus with reduced-dose calcineurin-inhibitor strategy may reduce the long-term risk of NMSC.
Collapse
Affiliation(s)
- Tracey Ying
- Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.,Kidney Node at Charles Perkins Centre, Sydney Medical School, University of Sydney, Camperdown, NSW, Australia
| | - Germaine Wong
- Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, Australia.,Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - Wai Lim
- Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.,University of Western Australia, Perth, WA, Australia
| | - John Kanellis
- Department of Nephrology, Monash Health and Centre for Inflammatory Diseases, Melbourne, Australia.,Department of Medicine, Monash University, Melbourne, Australia
| | - Helen Pilmore
- Department of Renal Medicine, Auckland Hospital, Auckland, VIC, New Zealand
| | - Scott Campbell
- Department of Renal Medicine, University of Queensland at Princess Alexandria Hospital, Woolloongabba, QLD, Australia
| | - Rosemary Masterson
- Department of Renal Medicine, Royal Melbourne Hospital, Parkville, VIC, Australia
| | - Rowan Walker
- Department of Renal Medicine, The Alfred Hospital Prahran, VIC, Australia
| | - Philip O'Connell
- Department of Renal Medicine, Westmead Hospital, Westmead, NSW, Australia
| | - Graeme Russ
- Central and Northern Adelaide Renal and Transplantation Services, Adelaide, SA, Australia
| | - Steven Chadban
- Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.,Kidney Node at Charles Perkins Centre, Sydney Medical School, University of Sydney, Camperdown, NSW, Australia
| |
Collapse
|
6
|
Sharma AK, Toussaint ND, Elder GJ, Masterson R, Holt SG, Robertson PL, Ebeling PR, Baldock P, Miller RC, Rajapakse CS. Magnetic resonance imaging based assessment of bone microstructure as a non-invasive alternative to histomorphometry in patients with chronic kidney disease. Bone 2018; 114:14-21. [PMID: 29860153 DOI: 10.1016/j.bone.2018.05.029] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Revised: 05/22/2018] [Accepted: 05/29/2018] [Indexed: 01/16/2023]
Abstract
BACKGROUND Chronic kidney disease (CKD) adversely affects bone microarchitecture and increases fracture risk. Historically, bone biopsy has been the 'gold standard' for evaluating renal bone disease but is invasive and infrequently performed. High-resolution magnetic resonance imaging (MRI) quantifies bone microarchitecture noninvasively. In patients with CKD, it has not been compared with results derived from bone biopsy or with imaging using dual energy X-ray absorptiometry (DXA). METHODS Fourteen patients with end-stage kidney disease (ESKD) underwent MRI at the distal tibia, bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA; hip and spine) and transiliac bone biopsies with histomorphometry and microcomputed tomography (micro-CT). All patients had biomarkers of mineral metabolism. Associations were determined by Spearman's or Pearson's rank correlation coefficients. RESULTS MRI indices of trabecular network integrity, surface to curve ratio (S/C) and erosion index (EI), correlated to histomorphometric trabecular bone volume (S/C r = 0.85, p = 0.0003; EI r = -0.82, p = 0.001), separation (S/C r = -0.58, p = 0.039; EI r = 0.79, p = 0.0012) and thickness (S/C, r = 0.65, p = 0.017). MRI EI and trabecular thickness (TbTh) also correlated to micro-CT trabecular separation (EI r = 0.63, p = 0.02; TbTh r = -0.60, p = 0.02). Significant correlations were observed between histomorphometric mineralization and turnover indices and various MRI parameters. MRI-derived trabecular parameters were also significantly related to femoral neck BMD. CONCLUSIONS This study highlights the heterogeneity of bone microarchitecture at differing skeletal sites. MRI demonstrates significant, relevant associations to important bone biopsy and DXA indices and warrants further investigation to assess its potential to non-invasively evaluate changes in bone structure and quality over time.
Collapse
Affiliation(s)
- Ashish K Sharma
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia; Department of Medicine (RMH), University of Melbourne, Parkville, Australia.
| | - Nigel D Toussaint
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia; Department of Medicine (RMH), University of Melbourne, Parkville, Australia
| | - Grahame J Elder
- Department of Renal Medicine, Westmead Hospital, Westmead, Australia; Osteoporosis and Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Rosemary Masterson
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia; Department of Medicine (RMH), University of Melbourne, Parkville, Australia
| | - Stephen G Holt
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia; Department of Medicine (RMH), University of Melbourne, Parkville, Australia
| | - Patricia L Robertson
- Department of Medicine (RMH), University of Melbourne, Parkville, Australia; Department of Radiology, The Royal Melbourne Hospital, Parkville, Australia
| | | | - Paul Baldock
- Osteoporosis and Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Rhiannon C Miller
- Departments of Radiology and Orthopaedic Surgery, University of Pennsylvania, PA, USA
| | - Chamith S Rajapakse
- Departments of Radiology and Orthopaedic Surgery, University of Pennsylvania, PA, USA
| |
Collapse
|
7
|
Sharma AK, Toussaint ND, Elder GJ, Rajapakse CS, Holt SG, Baldock P, Robertson PL, Ebeling PR, Sorci OR, Masterson R. Changes in bone microarchitecture following kidney transplantation-Beyond bone mineral density. Clin Transplant 2018; 32:e13347. [PMID: 29984421 DOI: 10.1111/ctr.13347] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Accepted: 07/03/2018] [Indexed: 11/30/2022]
Abstract
Bone disease in kidney transplant recipients (KTRs) is characterized by bone mineral density (BMD) loss but bone microarchitecture changes are poorly defined. In this prospective cohort study, we evaluated bone microarchitecture using non-invasive imaging modalities; high-resolution magnetic resonance imaging (MRI), peripheral quantitative computed tomography (pQCT), dual energy X-ray absorptiometry (DXA), and the trabecular bone score (TBS) following kidney transplantation. Eleven KTRs (48.3 ± 11.2 years) underwent MRI (tibia), pQCT (radius) and DXA at baseline and 12 months post-transplantation. Transiliac bone biopsies, performed at transplantation, showed 70% of patients with high/normal bone turnover. Compared with baseline, 12-month MRI showed deterioration in indices of trabecular network integrity-surface to curve ratio (S/C; -15%, P = 0.03) and erosion index (EI; +19%, P = 0.01). However, cortical area increased (+10.3%, P = 0.04), with a non-significant increase in cortical thickness (CtTh; +7.8%, P = 0.06). At 12 months, parathyroid hormone values (median 10.7 pmol/L) correlated with improved S/C (r = 0.75, P = 0.009) and EI (r = -0.71, P = 0.01) while osteocalcin correlated with CtTh (r = 0.72, P = 0.02) and area (r = 0.70, P = 0.02). TBS decreased from baseline (-5.1%, P = 0.01) with no significant changes in BMD or pQCT. These findings highlight a post-transplant deterioration in trabecular bone quality detected by MRI and TBS, independent of changes in BMD, underlining the potential utility of these modalities in evaluating bone microarchitecture in KTRs.
Collapse
Affiliation(s)
- Ashish K Sharma
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia
| | - Nigel D Toussaint
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia
| | - Grahame J Elder
- Department of Renal Medicine, Westmead Hospital, Westmead, Sydney, Australia.,Osteoporosis and Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | - Chamith S Rajapakse
- Departments of Radiology and Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Stephen G Holt
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia
| | - Paul Baldock
- Osteoporosis and Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | - Patricia L Robertson
- Department of Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia.,Department of Radiology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
| | | | - Olivia R Sorci
- Departments of Radiology and Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Rosemary Masterson
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia
| |
Collapse
|
8
|
Sharma AK, Toussaint ND, Masterson R, Holt SG, Rajapakse CS, Ebeling PR, Mohanty ST, Baldock P, Elder GJ. Deterioration of Cortical Bone Microarchitecture: Critical Component of Renal Osteodystrophy Evaluation. Am J Nephrol 2018; 47:376-384. [PMID: 29791896 DOI: 10.1159/000489671] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2017] [Accepted: 03/27/2018] [Indexed: 01/23/2023]
Abstract
BACKGROUND Cortical bone is a significant determinant of bone strength and its deterioration contributes to bone fragility. Thin cortices and increased cortical porosity have been noted in patients with chronic kidney disease (CKD), but the "Turnover Mineralization Volume" classification of renal osteodystrophy does not emphasize cortical bone as a key parameter. We aimed to assess trabecular and cortical bone microarchitecture by histomorphometry and micro-CT in patients with CKD G5 and 5D (dialysis). METHODS Transiliac bone biopsies were performed in 14 patients undergoing kidney transplantation (n = 12) and parathyroidectomy (n = 2). Structural parameters were analysed by histomorphometry and micro-CT including trabecular bone volume, thickness (TbTh), number (TbN) and separation and cortical thickness (CtTh) and porosity (CtPo). Indices of bone remodelling and mineralisation were obtained and relationships to bone biomarkers examined. Associations were determined by Spearman's or Pearson's rank correlation coefficients. RESULTS By micro-CT, trabecular parameters were within normal ranges in most patients, but all patients showed very low CtTh (127 ± 44 µm) and high CtPo (60.3 ± 22.5%). CtPo was inversely related to TbN (r = -0.56; p = 0.03) by micro-CT and to TbTh (r = -0.60; p = 0.024) by histomorphometry and correlated to parathyroid hormone values (r = 0.62; p = 0.021). By histomorphometry, bone turnover was high in 50%, low in 21% and normal in 29%, while 36% showed abnormal patterns of mineralization. Significant positive associations were observed between osteoblast surface, osteoclast surface, mineralization surface and bone turnover markers. CONCLUSIONS Deterioration of cortical -microarchitecture despite predominantly normal trabecular parameters reinforces the importance of comprehensive cortical evaluation in patients with CKD.
Collapse
Affiliation(s)
- Ashish K Sharma
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
- Department of Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia
| | - Nigel D Toussaint
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
- Department of Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia
| | - Rosemary Masterson
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
- Department of Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia
| | - Stephen G Holt
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
- Department of Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia
| | - Chamith S Rajapakse
- Departments of Radiology and Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | | | - Sindhu T Mohanty
- Osteoporosis and Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | - Paul Baldock
- Osteoporosis and Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | - Grahame J Elder
- Osteoporosis and Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
- Department of Renal Medicine, Westmead Hospital, Westmead, New South Wales, Australia
| |
Collapse
|
9
|
Masterson R. Book review. Int J Orthop Trauma Nurs 2017. [DOI: 10.1016/j.ijotn.2017.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Chow KV, Flint SM, Shen A, Landgren A, Finlay M, Murugasu A, Masterson R, Hughes P, Cohney SJ. Histological and Extended Clinical Outcomes After ABO-Incompatible Renal Transplantation Without Splenectomy or Rituximab. Transplantation 2017; 101:1433-1440. [DOI: 10.1097/tp.0000000000001415] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
11
|
Sharma AK, Masterson R, Holt SG, Tan SJ, Hughes PD, Chu M, Jayadeva P, Toussaint ND. Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients. Nephrology (Carlton) 2016; 21:46-54. [PMID: 26072678 DOI: 10.1111/nep.12536] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/08/2015] [Indexed: 11/30/2022]
Abstract
AIM Cinacalcet is effective in reducing parathyroid hormone (PTH) in patients on dialysis. Reports of biochemical profiles and other clinical outcomes in patients discontinuing cinacalcet at time of renal transplantation are limited. METHODS A retrospective study assessing markers of mineral metabolism, graft and patient outcomes in renal transplant recipients to determine differences in patients discontinuing cinacalcet (C+) compared with patients not treated with cinacalcet (C-) at time of transplantation. To allow for differences between groups in pre-transplant biochemical parameters, we also analysed a matched cohort of C- with C+ recipients (2:1), matched for age, calcium and PTH levels at transplantation. RESULTS Five hundred thirty-two recipients (460 C-, 72 C+), transplanted January 2006-December 2012, were analysed, mean age 48.0 ± 12.7 years and 64.3% were men. At a median 42.9 months follow up, there were 10 deaths (1.9%), 56 allograft loss (10.6%) and 5 parathyroidectomies post-transplant (0.8%). Median PTH immediately pre-transplant was higher in C+ versus C- (50.7(25.4-75.2) versus 28.3(13.9-49.7) pmol/L, P < 0.001). Twelve-month post-transplant PTH was reduced but higher in C+ (11.7(6.9-21.2) vs 7.2(4.6-11.2) pmol/L, P < 0.001). Mean calcium was higher for C+ versus C- at 12 months (2.50 ± 0.19 vs 2.43 ± 0.17 mmol/L, P < 0.001), with differences to 4 years post-transplant. No difference was seen in renal function, graft loss, post-transplant parathyroidectomy rate and mortality. In the matched cohort (144 C- vs 72 C+), similar findings were also seen. CONCLUSION Differences in mineral metabolism post-transplant are seen with cinacalcet pre-transplant compared with no cinacalcet. Transplant recipients discontinuing cinacalcet had higher post-transplant PTH and calcium although the clinical significance is unclear.
Collapse
Affiliation(s)
- Ashish K Sharma
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia.,Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia
| | - Rosemary Masterson
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia
| | - Stephen G Holt
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia.,Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia
| | - Sven-Jean Tan
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia.,Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia
| | - Peter D Hughes
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia
| | - Melissa Chu
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia
| | - Pavithra Jayadeva
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia
| | - Nigel D Toussaint
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia.,Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
12
|
Masterson R, Blair S, Polkinghorne KR, Lau KK, Lian M, Strauss BJ, Morgan JG, Kerr P, Toussaint ND. Low versus high dialysate calcium concentration in alternate night nocturnal hemodialysis: A randomized controlled trial. Hemodial Int 2016; 21:19-28. [PMID: 27364375 DOI: 10.1111/hdi.12452] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Higher calcium dialysate is recommended for quotidian nocturnal hemodialysis (NHD) (≥6 nights/week) to maintain bone health. It is unclear what the optimal calcium dialysate concentration should be for alternate night NHD. We aimed to determine the effect of low calcium (LC) versus high calcium (HC) dialysate on cardiovascular and bone parameters in this population. METHODS A randomized controlled trial where participants were randomized to LC (1.3 mmol/L, n = 24) or HC dialysate (1.6 or 1.75 mmol/L, n = 26). Primary outcome was change in mineral metabolism markers. Secondary outcomes included change in vascular calcification (VC) scores [CT abdominal aorta (AA) and superficial femoral arteries (SFA)), pulse wave velocity (PWV), bone mineral density (BMD) and left ventricular mass index (LVMI) over 12 months. FINDINGS In the LC group, pre-dialysis ionised calcium decreased -0.12 mmol/L (-0.18-0.06, P = 0.0001) and PTH increased 16 pmol/L (3.5-28.5, p = 0.01) from baseline to 12 months with no significant change in the HC group. In both groups, there was no progression of VC in AA or SFA and no change in PWV, LVMI or BMD. At 12 months, calcimimetics were prescribed in a higher percentage in the LC vs. HC groups (45.5% vs. 10.5%) with a lower proportion of the HC group being prescribed calcitriol (31.5% vs. 72%). DISCUSSION Although dialysate calcium prescription influenced biochemical parameters it was not associated with difference in progression of VC between HC and LC groups. An important finding was the potential impact of alternate night NHD in attenuating progression of VC and inducing stabilisation of LVMI and PWV.
Collapse
Affiliation(s)
- Rosemary Masterson
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
| | - Susan Blair
- Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia
| | - Kevan R Polkinghorne
- Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.,Department of Medicine, Monash University, Clayton, Victoria, Australia
| | - Kenneth K Lau
- Department of Radiology, Monash Medical Centre, Clayton, Victoria, Australia
| | - Michael Lian
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Boyd J Strauss
- Department of Medicine, Monash University, Clayton, Victoria, Australia
| | - John G Morgan
- Department of Cardiology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Peter Kerr
- Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.,Department of Medicine, Monash University, Clayton, Victoria, Australia
| | - Nigel D Toussaint
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
| |
Collapse
|
13
|
Masterson R. Book review. Int J Orthop Trauma Nurs 2016. [DOI: 10.1016/j.ijotn.2016.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Sharma AK, Masterson R, Holt SG, Toussaint ND. Emerging role of high-resolution imaging in the detection of renal osteodystrophy. Nephrology (Carlton) 2016; 21:801-11. [PMID: 27042945 DOI: 10.1111/nep.12790] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 03/14/2016] [Accepted: 03/25/2016] [Indexed: 12/17/2022]
Abstract
The term renal osteodystrophy refers to changes in bone morphology induced by chronic kidney disease (CKD) and represents the skeletal component of the entity 'chronic kidney disease - mineral and bone disorder'. Changes in turnover, mineralization, mass and microarchitecture impair bone quality, compromising strength and increasing susceptibility to fractures. Fractures are more common in CKD compared with the general population and result in increased morbidity and mortality. Screening for fracture risk and management of renal osteodystrophy are hindered by the complex, and still only partially understood, pathophysiology and the inadequacy of currently available diagnostic methods. Bone densitometry and bone turnover markers, although potentially helpful, have significant limitations in patients with CKD, and the 'gold standard' test of bone biopsy is infrequently performed in routine clinical practice. However, recent advances in high-resolution bone microarchitecture imaging may offer greater potential for quantification and assessment of bone structure and strength and, when used in conjunction with serum biomarkers, may allow non-invasive testing for a diagnostic virtual bone biopsy.
Collapse
Affiliation(s)
- Ashish K Sharma
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia
| | - Rosemary Masterson
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia
| | - Stephen G Holt
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.,Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia
| | - Nigel D Toussaint
- Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia. .,Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia.
| |
Collapse
|
15
|
Masterson R. Galway Orthopaedic Nursing Conference. Int J Orthop Trauma Nurs 2015. [DOI: 10.1016/j.ijotn.2015.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Cohney S, Masterson R, Hogan C, Hughes P, Haeusler M. ABOi with conventional immunosuppression alone-antiblood group antibody isn't the only contributor to antibody-mediated rejection and/or thrombotic microangiopathy. Am J Transplant 2015; 15:1730-2. [PMID: 25912527 DOI: 10.1111/ajt.13256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- S Cohney
- Nephrology Department, Royal Melbourne Hospital, Melbourne, Australia
| | - R Masterson
- Nephrology Department, Royal Melbourne Hospital, Melbourne, Australia
| | - C Hogan
- Hematology Laboratory, Royal Melbourne Hospital, Melbourne, Australia
| | - P Hughes
- Nephrology Department, Royal Melbourne Hospital, Melbourne, Australia
| | - M Haeusler
- Hematology Laboratory, Royal Melbourne Hospital, Melbourne, Australia
| |
Collapse
|
17
|
Sharma AK, Masterson R, Holt SG, Hughes PD, Chu M, Jayadeva P, Toussaint ND. SP658EFFECTS OF CINACALCET USE ON POST TRANSPLANT MINERAL METABOLISM. Nephrol Dial Transplant 2015. [DOI: 10.1093/ndt/gfv199.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Masterson R, Hughes P, Walker RG, Hogan C, Haeusler M, Robertson AR, Millar R, Suh N, Cohney SJ. ABO incompatible renal transplantation without antibody removal using conventional immunosuppression alone. Am J Transplant 2014; 14:2807-13. [PMID: 25389083 DOI: 10.1111/ajt.12920] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2014] [Revised: 06/23/2014] [Accepted: 06/25/2014] [Indexed: 01/25/2023]
Abstract
ABO incompatible living donor renal transplantation (ABOi) can achieve outcomes comparable to ABO compatible transplantation (ABOc). However, with the exception of blood group A2 kidneys transplanted into recipients with low titer anti-A antibody, regimens generally include antibody removal, intensified immunosuppression and splenectomy or rituximab. We now report a series of 20 successful renal transplants across a range of blood group incompatibilities using conventional immunosuppression alone in recipients with low baseline anti-blood group antibody (ABGAb) titers. Incompatibilities were A1 to O (3), A1 to B (2), A2 to O (2), AB to A (2), AB to B (1), B to A1 (9), B to O (1); titers 1:1 to 1:16 by Ortho. At 36 months, patient and graft survival are 100%. Antibody-mediated rejection (AbMR) occurred in one patient with thrombophilia and low level donor-specific anti-HLA antibody. Four patients experienced cellular rejection (two subclinical), which responded to oral prednisolone. This series demonstrates that selected patients with low titer ABGAb can undergo ABOi with standard immunosuppression alone, suggesting baseline titer as a reliable predictor of AbMR. This reduces morbidity and cost of ABOi for patients with low titer ABGAb and increases the possibility of ABOi from deceased donors.
Collapse
Affiliation(s)
- R Masterson
- Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Masterson R. Book review. Int J Orthop Trauma Nurs 2014. [DOI: 10.1016/j.ijotn.2014.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
20
|
Langsford D, Masterson R, Hughes P. Mycophenolate Loading in the First Week Post Renal Transplantation Increases the Risk of BK Viremia. Transplantation 2014. [DOI: 10.1097/00007890-201407151-01878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Pan FF, Hidayati L, Hughes P, Murugasu A, Masterson R. Case report: thrombotic microangiopathy post-intravenous immunoglobulin in the context of BK nephropathy and renal transplantation. Transplant Proc 2014; 46:278-80. [PMID: 24507067 DOI: 10.1016/j.transproceed.2013.10.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Accepted: 10/28/2013] [Indexed: 10/25/2022]
Abstract
Intravenous immunoglobulin (IVIg) is a blood product with immunomodulating properties that have been widely applied in the management of renal transplant recipients. In general, IVIg has been considered a relatively safe therapy, with most adverse events being mild and transient. Although rare, a serious and well-recognized complication of IVIg is large-vessel thrombotic events, which are thought to be related to hyperviscosity. We describe here two cases in which there was a temporal relationships between the administration of IVIg, an acute decline in allograft function, and the histologic finding of de novo thrombotic microangiopathy (TMA). In both cases, IVIg had been administered to facilitate immunosuppressive dose reduction in the context of BK nephropathy. We believe this is the first report of TMA associated with IVIg administration in renal allograft recipients.
Collapse
Affiliation(s)
- F F Pan
- Department of Nephrology, Royal Melbourne Hospital, Melbourne, Vic, Australia
| | - L Hidayati
- Department of Nephrology, Royal Melbourne Hospital, Melbourne, Vic, Australia
| | - P Hughes
- Department of Nephrology, Royal Melbourne Hospital, Melbourne, Vic, Australia; Department of Medicine, University of Melbourne, Melbourne, Vic, Australia
| | - A Murugasu
- Department of Anatomical Pathology, Royal Melbourne Hospital, Melbourne, Vic, Australia
| | - R Masterson
- Department of Nephrology, Royal Melbourne Hospital, Melbourne, Vic, Australia; Department of Medicine, University of Melbourne, Melbourne, Vic, Australia.
| |
Collapse
|
22
|
Masterson R. Book review. Int J Orthop Trauma Nurs 2014. [DOI: 10.1016/j.ijotn.2013.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Masterson R. Book review. Int J Orthop Trauma Nurs 2013. [DOI: 10.1016/j.ijotn.2013.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Masterson R. Book review. Int J Orthop Trauma Nurs 2013. [DOI: 10.1016/j.ijotn.2013.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Masterson R. BOOK REVIEW. Int J Orthop Trauma Nurs 2013. [DOI: 10.1016/j.ijotn.2012.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Brown MA, Crail SM, Masterson R, Foote C, Robins J, Katz I, Josland E, Brennan F, Stallworthy EJ, Siva B, Miller C, Urban AK, Sajiv C, Glavish RN, May S, Langham R, Walker R, Fassett RG, Morton RL, Stewart C, Phipps L, Healy H, Berquier I. ANZSN Renal Supportive Care Guidelines 2013. Nephrology (Carlton) 2013; 18:401-454. [DOI: 10.1111/nep.12065] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/02/2013] [Indexed: 12/16/2022]
Affiliation(s)
- Mark A Brown
- Departments of Renal Medicine and Medicine; St George Hospital and University of NSW; Sydney New South Wales Australia
| | - Susan M Crail
- Central and North Adelaide Renal and Transplantation Service; Adelaide South Australia Australia
- Central and North Adelaide Renal and Transplant Services; Adelaide South Australia Australia
| | - Rosemary Masterson
- Department of Nephrology; Royal Melbourne Hospital; Melbourne Victoria Australia
| | - Celine Foote
- The George Institute for Global Health; Sydney New South Wales Australia
| | - Jennifer Robins
- Departments of Renal Medicine and Medicine; St George Hospital and University of NSW; Sydney New South Wales Australia
| | - Ivor Katz
- Departments of Renal Medicine and Medicine; St George Hospital and University of NSW; Sydney New South Wales Australia
| | | | - Frank Brennan
- Departments of Renal Medicine and Palliative Medicine; St George Hospital; Kogarah New South Wales Australia
- Deparments of Renal Medicine and Palliative Medicine; St George Hospital; Kogarah New South Wales Australia
| | | | - Brian Siva
- Fremantle Hospital; Fremantle Western Australia Australia
| | - Cathy Miller
- Palliative Care Service; Department of General Medicine; North Shore and Waitakere Hospitals; Waitemata District Health Board; Auckland New Zealand
| | - A Katalin Urban
- Concord Repatriation Hospital; Concord; New South Wales Australia
| | - Cherian Sajiv
- Alice Springs Hospital; Central Australian Renal Services; Alice Springs Northern Territory Australia
| | - R Naida Glavish
- He Kamaka Oranga - Department of Maori Health; Auckland District Health Board; Auckland New Zealand
| | - Steven May
- Tamworth Base Hospital; Tamworth New South Wales Australia
| | | | - Robert Walker
- Department of Medicine; Dunedin School of Medicine; University of Otago; Dunedin New Zealand
| | - Robert G Fassett
- Royal Brisbane and Women's Hospital; Herston Queensland Australia
| | - Rachael L Morton
- School of Public Health; University of Sydney; Sydney New South Wales Australia
| | - Cameron Stewart
- Centre for Health Governance, Law & Ethics; Sydney Law School; University of Sydney; Sydney
| | - Lisa Phipps
- Orange Base Hospital; Orange New South Wales Australia
| | - Helen Healy
- Deparment of Renal Medicine; Royal Brisbane and Women's Hospital; Brisbane Queensland Australia
| | - Ilse Berquier
- Central and North Adelaide Renal and Transplant Services; Adelaide South Australia Australia
| |
Collapse
|
27
|
Masterson R, Foote C. Perspective - the issues surrounding ESKD and dialysis in the elderly and those with co-morbidities. Nephrology (Carlton) 2013:n/a-n/a. [PMID: 23586734 DOI: 10.1111/nep.12070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
There is a disproportionate increase in the number of elderly patients, many with multiple co-morbidities, commencing dialysis. Predictors of survival for elderly patients on dialysis include age, comorbidity score, malnutrition, poor functional status and late referral. Patients with high co morbidity scores may not gain a survival advantage with dialysis vs a non dialysis pathway. Late referral and lack of dialysis access are independent predictors of mortality in elderly patients commencing dialysis. Hospital free survival may be similar in dialysis and non-dialysis treated groups We have little data on those choosing not to start dialysis in terms of numbers, clinical course and survival. Most available data is not from an Australian or New Zealand source. The effects on quality of life of different management pathways on patients, carers and staff still need to be addressed.
Collapse
Affiliation(s)
| | - Celine Foote
- The George Institute for Global Health, Sydney, NSW
| |
Collapse
|
28
|
Jun M, Jardine MJ, Gray N, Masterson R, Kerr PG, Agar JW, Hawley CM, van Eps C, Cass A, Gallagher M, Perkovic V. Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. Am J Kidney Dis 2013; 61:247-53. [DOI: 10.1053/j.ajkd.2012.08.032] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2012] [Accepted: 08/13/2012] [Indexed: 11/11/2022]
|
29
|
Chadban SJ, Barraclough KA, Campbell SB, Clark CJ, Coates PT, Cohney SJ, Cross NB, Eris JM, Henderson L, Howell MR, Isbel NM, Kanellis J, Kotwal SS, Manley P, Masterson R, Mulley W, Murali K, O'Connell P, Pilmore H, Rogers N, Russ GR, Walker RG, Webster AC, Wiggins KJ, Wong G, Wyburn KR. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Nephrology (Carlton) 2012; 17:204-14. [PMID: 22212251 DOI: 10.1111/j.1440-1797.2011.01559.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Steven J Chadban
- Transplantation and Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Ruderman I, Masterson R, Yates C, Gorelik A, Cohney SJ, Walker RG. New onset diabetes after kidney transplantation in autosomal dominant polycystic kidney disease: a retrospective cohort study. Nephrology (Carlton) 2012; 17:89-96. [PMID: 21854501 DOI: 10.1111/j.1440-1797.2011.01507.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND New onset diabetes after transplantation (NODAT) is a common adverse outcome of organ transplantation that increases the risk of cardiovascular disease, infection and graft rejection. In kidney transplantation, apart from traditional risk factors, autosomal dominant polycystic kidney disease (ADPKD) has also been reported by several authors as a predisposing factor to the development of NODAT, but any rationale for an association between ADPKD and NODAT is unclear. We examined the cumulative incidence of NODAT in or own transplant population comparing ADPKD patients with non-ADPKD controls. METHODS A retrospective cohort study to determine the cumulative incidence of patients developing NODAT (defined by World Health Organization-based criteria and/or use of hypoglycaemic medication) was conducted in 79 patients with ADPKD (79 transplants) and 423 non-ADPKD controls (426 transplants) selected from 613 sequential transplant recipients over 8 years. Patients with pre-existing diabetes as a primary disease or comorbidity and/or with minimal follow up or early graft loss/death were excluded. RESULTS Of the 502 patients (505 transplants) studied, 86 (17.0%) developed NODAT. There was no significant difference in the cumulative incidence of NODAT in the ADPKD (16.5%; CI 13.6-20.7%) compared with the non-ADPKD (17.1%; CI 8.3-24.6%) control group. Of the 13 patients in the ADPKD group with NODAT, three required treatment with insulin with or without oral hypoglycaemic agents. Among the 73 NODAT patients in the non-ADPKD group, eight received insulin with or without oral hypoglycaemics. Furthermore, of the patients that did develop NODAT, there was no difference in the time to its development in patients with and without ADPKD. CONCLUSION There was no evidence of an increased incidence of NODAT in ADPKD kidney transplant recipients.
Collapse
Affiliation(s)
- Irene Ruderman
- Department of Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | | | | | | | | | | |
Collapse
|
31
|
Morton RL, Snelling P, Webster AC, Rose J, Masterson R, Johnson DW, Howard K. Dialysis modality preference of patients with CKD and family caregivers: a discrete-choice study. Am J Kidney Dis 2012; 60:102-11. [PMID: 22417786 DOI: 10.1053/j.ajkd.2011.12.030] [Citation(s) in RCA: 88] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2011] [Accepted: 12/29/2011] [Indexed: 11/11/2022]
Abstract
BACKGROUND Dialysis modality preferences of patients with chronic kidney disease (CKD) and family caregivers are important, yet rarely quantified. STUDY DESIGN Prospective, unlabeled, discrete-choice experiment with random-parameter logit analysis. SETTING & PARTICIPANTS Adults with stages 3-5 CKD and caregivers educated about dialysis treatment options from 8 Australian renal clinics. PREDICTORS Preferences for and trade-offs between the dialysis treatment attributes of life expectancy, number of hospital visits per week, ability to travel, hours per treatment, treatment time of day, subsidized transport service, and flexibility of treatment schedule. OUTCOMES & MEASUREMENTS Results presented as ORs for preferring home-based or in-center dialysis to conservative care. RESULTS 105 predialysis patients and 73 family caregivers completed the study. Median patient age was 63 years, and mean estimated glomerular filtration rate was 18.1 (range, 6-34) mL/min/1.73 m(2). Median caregiver age was 61 years. Home-based dialysis (either peritoneal or home hemodialysis) was chosen by patients in 65% of choice sets; in-center dialysis, in 35%; and conservative care, in 10%. For caregivers, this was 72%, 25%, and 3%, respectively. Both patients and caregivers preferred longer rather than shorter hours of dialysis (ORs of 2.02 [95% CI, 1.51-2.70] and 2.67 [95% CI, 1.85-3.85] for patients and caregivers, respectively), but were less likely to choose nocturnal than daytime dialysis (ORs of 0.07 [95% CI, 0.01-0.75] and 0.03 [95% CI, 0.01-0.20]). Patients were willing to forgo 23 (95% CI, 19-27) months of life expectancy with home-based dialysis to decrease their travel restrictions. For caregivers, this was 17 (95% CI, 16-18) patient-months. LIMITATIONS Data were limited to stated preferences rather than actual choice of dialysis modality. CONCLUSIONS Our study suggests that it is rare for caregivers to prefer conservative nondialytic care for family members with CKD. Home-based dialysis modalities that enable patients and their family members to travel with minimal restriction would be strongly aligned with the preferences of both parties.
Collapse
Affiliation(s)
- Rachael L Morton
- Sydney School of Public Health, The University of Sydney, NSW, Australia.
| | | | | | | | | | | | | |
Collapse
|
32
|
Morton RL, Snelling P, Webster AC, Rose J, Masterson R, Johnson DW, Howard K. Factors influencing patient choice of dialysis versus conservative care to treat end-stage kidney disease. CMAJ 2012; 184:E277-83. [PMID: 22311947 DOI: 10.1503/cmaj.111355] [Citation(s) in RCA: 138] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND For every patient with chronic kidney disease who undergoes renal-replacement therapy, there is one patient who undergoes conservative management of their disease. We aimed to determine the most important characteristics of dialysis and the trade-offs patients were willing to make in choosing dialysis instead of conservative care. METHODS We conducted a discrete choice experiment involving adults with stage 3-5 chronic kidney disease from eight renal clinics in Australia. We assessed the influence of treatment characteristics (life expectancy, number of visits to the hospital per week, ability to travel, time spent undergoing dialysis [i.e., time spent attached to a dialysis machine per treatment, measured in hours], time of day at which treatment occurred, availability of subsidized transport and flexibility of the treatment schedule) on patients' preferences for dialysis versus conservative care. RESULTS Of 151 patients invited to participate, 105 completed our survey. Patients were more likely to choose dialysis than conservative care if dialysis involved an increased average life expectancy (odds ratio [OR] 1.84, 95% confidence interval [CI] 1.57-2.15), if they were able to dialyse during the day or evening rather than during the day only (OR 8.95, 95% CI 4.46-17.97), and if subsidized transport was available (OR 1.55, 95% CI 1.24-1.95). Patients were less likely to choose dialysis over conservative care if an increase in the number of visits to hospital was required (OR 0.70, 95% CI 0.56-0.88) and if there were more restrictions on their ability to travel (OR=0.47, 95%CI 0.36-0.61). Patients were willing to forgo 7 months of life expectancy to reduce the number of required visits to hospital and 15 months of life expectancy to increase their ability to travel. INTERPRETATION Patients approaching end-stage kidney disease are willing to trade considerable life expectancy to reduce the burden and restrictions imposed by dialysis.
Collapse
Affiliation(s)
- Rachael L Morton
- Sydney School of Public Health, the University of Sydney, Sydney, Australia.
| | | | | | | | | | | | | |
Collapse
|
33
|
Walker R, Ruderman I, Masterson R, Cohney S, Salvadori M, Conti P, Bertoni E, Durrbach A, Citterio F, Mulloy L, David-Neto E, Russ G, Vitko S, Zhang R, Xing J, Harler MB, Grinyo J, Rugiu C, Trubian A, Bernich P, Lupo A, Asbe-Vollkopf A, Pannu A, Hoefeld H, Gauer S, Gossmann J, Kachel HG, Froese S, Korom S, Geiger H, Hauser IA, Liefeldt L, Kluener C, Glander P, Giessing M, Gralla O, Neumayer HH, Budde K, Kroencke T, Liborio AB, Barros RM, Esmeraldo RM, Oliveira MLMB, Nogueira Paes FJV, Mendoza TR, Silva Junior GB, Daher EF, Siekierka-Harreis M, Bantis C, Kouri NM, Schwandt C, Rump LC, Ivens K, Slatinska J, Honsova E, Burgelova M, Slimackova E, Viklicky O, Tabernero G, Rivero K, Fernandez G, Canueto J, Garcia P, Fraile P, Lucas C, Tabernero JM, Bargnoux AS, Simon N, Garrigue V, Dupuy AM, Mourad G, Cristol JP, Yapici U, Kers J, Bemelman F, Roelofs J, Groothoff J, van der Loos C, van Donselaar-van der Pant K, Idu M, Claessen N, ten Berge I, Florquin S, Knap B, Dragonja Z, Dobnik S, Buturovic Ponikvar J, Ponikvar R, Kandus A, Bren A, Hauser IA, Kleemann J, Gauer S, Engel J, Winter S, Hoefeld H, Asbe-Vollkopf A, Brzoska M, Obermueller N, Geiger H, Schaeffeler E, Oldak M, Pazik J, Lewandowski Z, Sitarek E, Dabrowski M, Ploski R, Malejczyk J, Durlik M, Slubowska K, Urbanowicz A, Sadowska A, Lichodziejewska B, Kurnicka K, Galazka Z, Chmura A, Durlik M, Masin-Spasovska J, Spasovski G, Petrusevska G, Popov Z, Ivanovski N, Di Napoli A, Salvatori MF, Franco F, Di Lallo D, Guasticchi G, Sancho A, Gavela E, Beltran S, Kanter J, Alemany B, Crespo JF, Pallardo LM, Lionet A, Beuscart JB, Buob D, BenHenda A, Provot F, Hazzan M, Noel C, Galan-Sanchez F, Marin-Casanova P, Mazuecos A, Garcia-Alvarez T, Aznar E, Rodriguez-Iglesias M, Ossareh S, Salami M, Mohammad E, Hosseini M, Pawlik A, Chudek J, Kolonko A, Wilk J, Jalowiecki P, Wiecek A, Zyablitskaya E, Galkina E, Yushina E, Botelho C, Aires P, Santos L, Romaozinho C, Macario F, Alves R, Veiga P, Mota A, Yashi M, Yagisawa T, Kimura T, Nukui A, Fujiwara T, Sakuma Y, Ishikawa N, Iwabuchi T, Muraishi O, Glander P, Hambach P, Liefeldt L, Neumayer HH, Budde K, Esmen S, Keven K, Sengul S, Ozcan M, Ensari A, Tuzuner A, Calayoglu R, Nergizoglu G, Gullu Koca T, Koca N, Ersoy A, Faria B, Bustorff M, Barros F, Tavares I, Santos J, Ferreira I, Sampaio S, Pestana M, Keven K, Suvak B, Sengul S, Kurultak I, Calayoglu R, Tutkak H, Choi HM, Yang HN, Jo SK, Cho WY, Kim HK, Aybal Kutlugun A, Altun B, Akman U, Aki T, Turkmen E, Yildirim T, Altindal M, Yilmaz R, Yasavul U, Gullu Koca T, Koca N, Ersoy A, Thiem U, Heinze G, Gossler U, Perkmann T, Kainberger F, Muhlbacher F, Horl W, Borchhardt K, Sanchez-Escuredo A, Holgado S, Biosca C, Granada ML, Barluenga E, Lauzurica R, Romero R, Espinal A, Torregrossa V, Bayes B, Tomida K, Hamano T, Fujii N, Ichimaru N, Matsui I, Isaka Y, Rakugi H, Takahara S, Gavela E, Sancho A, Kanter J, Beltran S, Avila A, Crespo JF, Pallardo LM, Dor F, Massey E, Frunza M, Johnson R, Lennerling A, Loven C, Mamode N, Pascalev A, Sterckx S, Van Assche K, Zuidema W, Weimar W, Botelho C, Aires P, Santos L, Romaozinho C, Macario F, Alves R, Veiga P, Mota A, Allwin R, Gauer S, Roessel, Hoefeld H, Brzoska M, Buettner S, Gossmann J, Belwe V, Geiger H, Hauser IA, Apaza J, Gonzalez E, Polanco N, Bengoa I, Cadenillas C, Andres A, Morales JM, Rocha S, Fonseca I, Martins LS, Vidinha J, Dias L, Almeida M, Pedroso S, Henriques A, Cabrita A, Neretljak I, Mihovilovic K, Vidas Z, Jurenec F, Knotek M, Justa S, Minz R, Minz M, Anand S, Sharma A, Lacquaniti A, Donato V, Chirico V, Pettinato G, Buemi M, Galle J, Addison J, Perry P, Claes K, Farouk M, Guerin A, Kiss I, Winearls C, Di Giulio S, Basic-Jukic N, Slavicek J, Bubic-Filipi L, Kes P, Scholbach T, Wang HK, Yang AH, Loong CC, Wu TH, Abboud I, Antoine C, Serrato T, Lefaucheur C, Pillebout E, Gaudez F, Fieux F, Flamant M, Verine J, Viglietti D, Peraldi MN, Glotz D. Transplantation: clinical studies (2). Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
|
35
|
Baweja S, Kent A, Masterson R, Roberts S, McMahon LP. Prediction of pre-eclampsia in early pregnancy by estimating the spot urinary albumin: creatinine ratio using high-performance liquid chromatography. BJOG 2011; 118:1126-32. [DOI: 10.1111/j.1471-0528.2011.02960.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Abstract
In this chapter we describe a reliable and reproducible method for the selective propagation and culture of renal fibroblasts derived from explantation of renal cortical tissue in vitro. The chapter outlines how primary renal interstitial fibroblasts are derived from explants grown in medium supplemented with foetal calf serum. The subculture of confluent cells and their ultimate characterisation as fibroblasts through immunohistochemical and immunocytochemical techniques are described in detail.
Collapse
Affiliation(s)
- Lauren Grimwood
- Department of Nephrology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | | |
Collapse
|
37
|
Abstract
In Australia, 12% of the hemodialysis population dialyze at home. Until recently, the majority of these patients dialyzed for similar hours to those in satellite dialysis. However, in the past 5 years there has been a new departure such that in many centers the concept of home hemodialysis is now synonymous with extended hours dialysis. Registry data supports the concept that increased frequency and duration of dialysis may result in improved patient survival and a reduction in cardiovascular risk profile. It is hoped, therefore, that the long recognized survival benefit observed in home hemodialysis patients may be further augmented by the swing to extended hours dialysis in this patient population. In addition to the physiological benefits of extended hours home dialysis, there are clear quality of life, social, and economic advantages associated with dialyzing at home. There are however a number of perceived disadvantages to home hemodialysis including the application and time commitment required for training, the potential for relationship strain or "burnout," and reluctance to "hospitalize" the home. Overall, however, in this new era of extended hours dialysis, the advantages both physiological and lifestyle of home hemodialysis far outweigh the disadvantages.
Collapse
Affiliation(s)
- Rosemary Masterson
- Department of Nephrology, Royal Melbourne Hospital, Parkville, Melbourne, Victoria, Australia.
| |
Collapse
|
38
|
Flint S, Masterson R, Walker R, Fraser I, Robertson A, Francis D, Millar R, Cohney S. ABO-INCOMPATIBLE RENAL TRANSPLANTATION WITHOUT SPLENECTOMY OR RITUXIMAB – LOW REJECTION RATES, LOW MORBIDITY AND EXCELLENT CLINICAL OUTCOMES. Transplantation 2008. [DOI: 10.1097/01.tp.0000330966.01719.89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Hewitson TD, Mookerjee I, Masterson R, Zhao C, Tregear GW, Becker GJ, Samuel CS. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology 2007; 148:660-9. [PMID: 17095590 DOI: 10.1210/en.2006-0814] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Relaxin is a naturally occurring regulator of collagen turnover. In this study, we determined the role of endogenous relaxin in the pathogenesis of primary tubulointerstitial fibrosis after unilateral ureteric obstruction (UUO). Four- to 6-wk-old relaxin (RLX) gene-knockout (RLX(-/-)) and age-matched wild-type (RLX(+/+)) mice, with equivalent baseline collagen levels, were subjected to UUO. Obstructed and contralateral kidneys were collected at d 0, 3, and 10 after surgery and analyzed for changes in inflammatory and fibrosis-related markers. UUO was associated with a progressive increase in fibrosis in all obstructed, but not contralateral kidneys. The increase in total collagen (hydroxyproline analysis) was associated with more alpha-smooth muscle actin (alpha-SMA) staining (myofibroblasts) and interstitial collagen sub-types (SDS-PAGE; types I, III, and V), whereas gelatin zymography demonstrated increased expression of matrix metalloproteinase-2 after surgery. By d 10 after UUO, there was a 5-fold decrease in RLX mRNA expression (quantitative RT-PCR) in RLX(+/+) animals. Total collagen and alpha-SMA expression were significantly greater in the obstructed kidneys of RLX(-/-) mice 3 d after UUO (both P < 0.05 vs. RLX(+/+) D3 after UUO), but comparable to that in RLX(+/+) animals 10 d after UUO. Administration of recombinant H2 relaxin to RLX(-/-) mice 4 d before UUO ameliorated the increase in collagen and alpha-SMA expression (both P < 0.05 vs. untreated RLX(-/-) mice) by d 3 after UUO. Expression of monocyte chemoattractant protein-1 and macrophage infiltration (inflammation) in addition to that of matrix metalloproteinases was unaffected by genotype after UUO. These combined data demonstrate that endogenous RLX acts as a modulating factor in tubulointerstitial fibrosis, a hallmark of progressive renal disease. This is likely to be via direct effects on renal myofibroblast function.
Collapse
Affiliation(s)
- Tim D Hewitson
- Howard Florey Institute, University of Melbourne, Parkville, Victoria 3010, Australia.
| | | | | | | | | | | | | |
Collapse
|
40
|
Samuel CS, Mookerjee I, Masterson R, Tregear GW, Hewitson TD. Relaxin regulates collagen overproduction associated with experimental progressive renal fibrosis. Ann N Y Acad Sci 2005; 1041:182-4. [PMID: 15956704 DOI: 10.1196/annals.1282.026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Progressive fibrosis due to excess extracellular matrix (primarily collagen) is the final common pathway in all forms of chronic renal disease, regardless of etiology, and leads to tissue dysfunction, when normal tissue is replaced by scar tissue. Emerging work from ourselves and others suggests that the naturally occurring hormone relaxin has the potential to limit renal collagen production and reorganization, while increasing its degradation. The outlined studies demonstrate relaxin's potential as an antifibrotic agent against experimental progressive renal disease.
Collapse
Affiliation(s)
- Chrishan S Samuel
- Howard Florey Institute of Experimental Physiology & Medicine, University of Melbourne, Parkville, Victoria 3010, Australia.
| | | | | | | | | |
Collapse
|
41
|
Masterson R, Kelynack K, Hewitson T, Becker G. Effect of inhibition of farnesylation and geranylgeranylation on renal fibrogenesis in vitro. Nephron Clin Pract 2005; 102:e19-29. [PMID: 16179803 DOI: 10.1159/000088403] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2004] [Accepted: 07/04/2005] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The Ras and Rho family of GTPases serve as essential molecular switches in the downstream signalling of many cytokines involved in the regulation of renal fibroblast activity. Prenylation is a post-translational process critical to the membrane localization and function of these GTPases. We studied the effects of a farnesyltransferase inhibitor BMS-191563 and geranylgeranyltransferase inhibitor GGTI-298 on renal fibrogenesis in vitro. METHODS Functional studies examined the effects of BMS-191563 and GGTI-298 on rat renal fibroblast kinetics, collagen synthesis and collagen gel contraction. Pro-collagen alpha1(I) mRNA expression was measured by Northern analysis and CTGF expression by Western blotting. RESULTS Fibroblast proliferation was significantly reduced by both agents. Exposure of fibroblasts to BMS-191563 resulted in a significant reduction in total collagen production and pro-collagen alpha1(I) mRNA expression, an effect also observed but to a lesser degree with GGTI-298. Both agents significantly reduced CTGF protein expression. Fibroblast-mediated collagen I lattice contraction was decreased at 48 h by GGTI-298, an effect not observed with BMS-191563. Consistent with this finding, marked actin filament disassembly was evident by phalloidin staining of fibroblasts exposed to GGTI-298. CONCLUSION BMS-191563 and GGTI-298 exhibit different effects on renal fibroblast function reflecting their predominant roles in inhibiting prenylation of Ras or Rho proteins respectively. Further studies are warranted to establish their potential therapeutic application in the treatment of progressive renal disease.
Collapse
Affiliation(s)
- Rosemary Masterson
- Department of Nephrology, Royal Melbourne Hospital, Melbourne, Australia.
| | | | | | | |
Collapse
|
42
|
Abstract
BACKGROUND Statins are antilipidemic agents that exhibit a variety of cellular effects independent of their lipid-lowering action. A retrospective study was undertaken to establish the impact of statins on graft outcome in the first year posttransplantation. METHODS Data from patients with uniform immunosuppression (cyclosporine, mycophenolate mofetil, and prednisolone) who underwent transplantation at the authors' unit from 1997 to 2002 were reviewed. Patients prescribed statins were compared with those not on a statin. Mean change in creatinine clearance (CrCl) from 3 to 12 months posttransplantation was calculated. Histomorphometric analysis was used to quantify fractional interstitial area and collagen III deposition in matched preperfusion and 12-month protocol biopsy specimens. RESULTS Seventy-seven patients met study criteria: statin, n=44 patients; nonstatin, n=33 patients. Median time to commencing a statin was 5 weeks. At 3 months, CrCl (+/-SEM) was similar: 51.6+/-2.9 mL/min (statin) versus 51.3+/-1 mL/min (nonstatin). At 12 months, the mean change in CrCl was 4.1+/-1 mL/min (statin) compared with -2.0+/-1.8 mL/min (nonstatin), resulting in a difference of 6.13 mL/min at 12 months (P<0.005). Mean preperfusion fractional interstitial areas were similar (23.9+/-1.6%; P=not significant [NS]). On 12-month biopsy specimens, the fractional interstitial area had increased to 34+/-3.2% in the nonstatin group (P<0.005), with no change in the statin group. Interstitial collagen III deposition was similar in preperfusion biopsy specimens (10.4+/-1%; P=NS), but at 12 months it was significantly greater in the nonstatin group (17.6+/-1%; P<0.05) CONCLUSIONS Early introduction of statins may be associated with improved 1-year graft outcome.
Collapse
Affiliation(s)
- Rosemary Masterson
- Department of Nephrology, Royal Melbourne Hospital, Parkville, Melbourne, Victoria, Australia.
| | | | | | | | | | | |
Collapse
|
43
|
Perkovic V, Craig JC, Masterson R, Webster A. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2004. [DOI: 10.1002/14651858.cd005019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
44
|
Masterson R, Pellicano R, Bleasel K, McMahon LP. Wegener's granulomatosis in pregnancy: a novel approach to management. Am J Kidney Dis 2004; 44:e68-72. [PMID: 15384037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
Wegener's granulomatosis rarely is diagnosed in women of childbearing age and is, thus, uncommonly encountered in pregnancy. Although conventional treatment with steroids and cyclophosphamide controls disease activity in 90% of patients, the associated teratogenicity of such a regimen warrants careful consideration in pregnancy. We describe successful remission induction with the use of intravenous immunoglobulin and steroids alone in a woman diagnosed with de novo Wegener's granulomatosis during the first trimester of pregnancy.
Collapse
Affiliation(s)
- Rosemary Masterson
- Department of Nephrology, Royal Melbourne Hospital, Parkville, Melbourne, Victoria, Australia.
| | | | | | | |
Collapse
|
45
|
|
46
|
Masterson R, Hewitson TD, Kelynack K, Martic M, Parry L, Bathgate R, Darby I, Becker G. Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant 2004; 19:544-52. [PMID: 14767007 DOI: 10.1093/ndt/gfg598] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Renal fibroblasts are important effector cells in tubulointerstitial fibrosis, with experimental antifibrotic strategies focusing on the functional down-regulation of these cells. Several experimental models of fibrosis have provided evidence for the effectiveness of the polypeptide hormone relaxin as a potential antifibrotic agent. This study was conducted to further elucidate the antifibrotic mechanisms of relaxin on renal fibroblasts in vitro. METHODS Rat cortical fibroblasts were obtained from outgrowth culture of renal tissue isolated from kidneys 3 days post-unilateral ureteric obstruction and constituted 100% of cells studied. A relaxin radio-receptor assay was used to establish binding of relaxin to renal fibroblasts in vitro. Functional studies then examined the effects of H2 relaxin (0, 1, 10 and 100 ng/ml) on fibroblast kinetics, expression of alpha-smooth muscle actin (alpha-SMA), total collagen synthesis, collagenase production and collagen-I lattice contraction. CTGF mRNA expression was also measured by northern analysis. RESULTS H2 relaxin bound with high affinity to rat renal fibroblasts, but receptor numbers were low. Consistent with its previously reported bimodal effect, transforming growth factor (TGF-beta 1) reduced fibroblast proliferation, an effect abrogated by H2 relaxin. Fibroblasts exposed to H2 relaxin (100 ng/ml) for 24 h demonstrated decreased immunostaining for alpha-SMA and reduced alpha-SMA protein expression compared with controls. There was a trend for a relaxin-mediated reduction in total collagen synthesis and alpha 1(I) mRNA expression with large dose-related increases in collagenase protein expression being observed. TGF-beta 1-stimulated collagen-I lattice contraction was significantly inhibited following co-incubation with 100 ng/ml relaxin. Incremental doses of H2 relaxin had no significant effect on CTGF mRNA expression. CONCLUSIONS The findings of this study suggest that the antifibrotic effects of relaxin involve down-regulation of fibroblast activity, increase in collagenase synthesis and restructuring of collagen-I lattices, which are consistent with its known physiological role of matrix remodelling. Although there appears to be an interaction between TGF-beta 1 and H2 relaxin, this does not appear to involve a reduction in CTGF mRNA expression.
Collapse
Affiliation(s)
- Rosemary Masterson
- Department of Nephrology, Royal Melbourne Hospital, and Department of Medicine, University of Melbourne, Victoria, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
A retrospective survey was performed to establish patient and graft outcome for all 41 patients at our centre receiving sirolimus (SRL) in combination with calcineurin inhibition (CNI) as primary therapy for the 6 years prior to March 2002. Patient mortality [12%; n = 5 (TTP, lymphoma, mucormycosis, and small bowel perforation] was significantly higher at 3 months compared with those not receiving SRL, but not thereafter. 12.8% had delayed graft function and 33% had one or more episodes of rejection in the first 6 months. Mean GFR at 12 months was significantly lower (47.3 mL/min) in the SRL group compared with those not receiving SRL (51.3 mL/min). Twenty-two patients had a 12-month protocol biopsy; CNI toxicity was present in 36%. SRL was associated with significant hyperlipidaemia (serum cholesterol, 5.2 +/- 1.4 at baseline vs 7.3 +/- 1.7 mmol/L at 3 months, P <.001; triglycerides, 2.3 +/- 1.4 at baseline vs 2.7 +/- 1.1 mmol/L at 3 months, P <.05). Mild thrombocytopenia occurred in 23% but was not associated with haemorrhagic events. LDH increased by 62%, remaining elevated out to 2 years post engraftment. Seven patients developed insulin requiring diabetes mellitus, similar to the rate observed in our general transplant population.Thus, in this early experience, SRL in combination with CNI was associated with significant mortality and morbidity including CNI toxicity, presumably a reflection of a heavy burden of immunosuppression. However, 1-year graft survival on SRL was similar to the mean Australia-wide graft survival regardless of immunosuppression. The future use of SRL may center around CNI sparing and avoidance type protocols.
Collapse
Affiliation(s)
- R Masterson
- Department of Nephrology, Royal Melbourne Hospital and Department of Medicine, University of Melbourne, Parkville, Australia
| | | | | | | | | |
Collapse
|
48
|
Masterson R, Sheerin N, Abbs I, Goldsmith D. Late allograft loss due to recurrence of p-ANCA-associated systemic vasculitis in a patient with relapsing polychondritis. Nephrol Dial Transplant 2001; 16:1705-7. [PMID: 11477180 DOI: 10.1093/ndt/16.8.1705] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Affiliation(s)
- R Masterson
- Department of Renal Medicine and Transplantation, Guy's Hospital, London, UK
| | | | | | | |
Collapse
|
49
|
Masterson R, Scoble J, Taylor P, Cook G. Recovery of renal function following prolonged ischaemia in a patient with Mid-Aortic Syndrome. Nephrol Dial Transplant 2000; 15:1461-3. [PMID: 10978411 DOI: 10.1093/ndt/15.9.1461] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- R Masterson
- Department of Renal Medicine and Transplantation, Guy's Hospital, London, UK
| | | | | | | |
Collapse
|
50
|
Southgate HJ, Masterson R. Lessons to be learned: a case study approach: prolonged methaemoglobinaemia due to inadvertent dapsone poisoning; treatment with methylene blue and exchange transfusion. J R Soc Promot Health 1999; 119:52-5. [PMID: 10327817 DOI: 10.1177/146642409911900111] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The authors present a case of methaemoglobinaemia of acute onset, with an unusually protracted course. The long persistence of this disorder led to a search for the cause which was eventually traced to medication with dapsone. The latter was found to be inappropriately being taken by the patient instead of an antispasmodic that had been prescribed for a spinal condition; this was because the tablets had been incorrectly labelled and dispensed in a pharmacy. The patient took increasing doses of the presumed 'antispasmodic' tablets as they seemed to lack clinical effect, thus further exacerbating the toxic consequences. Moreover, the patient brought his wrongly labelled tablets into hospital and was allowed to use them there, contrary to normal hospital policy. As treatment for the methaemoglobinaemia both bolus and continuous infusions of methylene blue were used, which probably contributed to the severe haemolysis which followed. Furthermore, the development of a rare side effect of dapsone toxicity, namely that of a sensorimotor neuropathy, is reported.
Collapse
|